


SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease
SB-007 is the only IND-cleared, clinical-stage therapeutic…

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy
Statistically significant difference in arrested disease in leriglitazone…

iOnctura reaches new clinical milestones in uveal melanoma
Completed Phase I DIONE-01 study demonstrates clinical activity…

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225
NorthStar will supply non-carrier added Actinium-225, a radionuclide,…

Industry leading survey of Venture Capital (VC) life sciences investors of funds managing c.$300bn
VCs favouring new investments over existing portfolio and have…

Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
EQT Life Sciences expands the Series B with additional capital,…

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis
Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics…

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
All doses of POLB 001 significantly reduced clinically observed…

NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)
London, UK, Barcelona, Spain and Düsseldorf, Germany – 5…

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
Berlin, Germany, December 5, 2024 – Ariceum Therapeutics (Ariceum),…

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
Agreement grants access to Synaffix patent portfolio related…

Antag Therapeutics Announces €80 Million Series A Financing
Antag Therapeutics, a next-generation biopharmaceutical company…

Novo Holdings to acquire Benchmark Genetics, a leader in aquaculture genetics
Novo Holdings today announced that it has agreed to acquire the…

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans
Vicebio enters the second stage of its Phase 1 Clinical Study…

Poolbeg Pharma plc – POLB 001 Patent Granted in United States
Further strengthens Poolbeg's robust intellectual property portfolio
20…

Women’s Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
Strategic investment from the Bill & Melinda Gates Foundation…

Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain
EMERALD Study will investigate the safety and efficacy of…

Denmark’s new AI supercomputer Gefion ranks 21 on the world’s TOP500 list
The Danish Centre for AI Innovation (DCAI) proudly announces…

BrightHeart Secures FDA Clearance for First AI Software Revolutionizing Prenatal Fetal Heart Ultrasound Evaluations
Paris, France – November 18th, 2024 – BrightHeart, a leading…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York